Evidence map›Paper›PMID 26052948›Full record

ArticlePloS one2015

Induction of Neuron-Specific Degradation of Coenzyme A Models Pantothenate Kinase-Associated Neurodegeneration by Reducing Motor Coordination in Mice.

Stephanie A Shumar, Paolo Fagone, Adolfo Alfonso-Pecchio, John T Gray, Jerold E Rehg, Suzanne Jackowski, Roberta Leonardi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. PKAN pathogenesis and treatment.Molecular genetics and metabolism · 2022
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stephanie A ShumarDepartment of Biochemistry, School of Medicine, West Virginia University, Morgantown, West Virginia, United States of America.
Paolo FagoneDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Adolfo Alfonso-PecchioDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
John T GrayDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Jerold E RehgDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Suzanne JackowskiDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Roberta LeonardiDepartment of Biochemistry, School of Medicine, West Virginia University, Morgantown, West Virginia, United States of America.
St. Jude Children's Research Hospital · USWest Virginia University · US

Funding

Regulation of Coenzyme A Levels by Pantothenate KinaseR01GM062896 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI JACKOWSKI, SUZANNE · 2002 to 2014
$4.0M
NIGMS NIH HHS GM062896NIGMS NIH HHS R01 GM062896
6 · The paper itself

Abstract

backgroundPantothenate kinase-associated neurodegeneration, PKAN, is an inherited disorder characterized by progressive impairment in motor coordination and caused by mutations in PANK2, a human gene that encodes one of four pantothenate kinase (PanK) isoforms. PanK initiates the synthesis of coenzyme A (CoA), an essential cofactor that plays a key role in energy metabolism and lipid synthesis. Most of the mutations in PANK2 reduce or abolish the activity of the enzyme. This evidence has led to the hypothesis that lower CoA might be the underlying cause of the neurodegeneration in PKAN patients; however, no mouse model of the disease is currently available to investigate the connection between neuronal CoA levels and neurodegeneration. Indeed, genetic and/or dietary manipulations aimed at reducing whole-body CoA synthesis have not produced a desirable PKAN model, and this has greatly hindered the discovery of a treatment for the disease. OBJECTIVE, METHODS, RESULTS AND

conclusionsCellular CoA levels are tightly regulated by a balance between synthesis and degradation. CoA degradation is catalyzed by two peroxisomal nudix hydrolases, Nudt7 and Nudt19. In this study we sought to reduce neuronal CoA in mice through the alternative approach of increasing Nudt7-mediated CoA degradation. This was achieved by combining the use of an adeno-associated virus-based expression system with the synapsin (Syn) promoter. We show that mice with neuronal overexpression of a cytosolic version of Nudt7 (scAAV9-Syn-Nudt7cyt) exhibit a significant decrease in brain CoA levels in conjunction with a reduction in motor coordination. These results strongly support the existence of a link between CoA levels and neuronal function and show that scAAV9-Syn-Nudt7cyt mice can be used to model PKAN.

Indexed as

Motor ActivityAnimalsCoenzyme AMiceMice, Inbred C57BLNeuronsNudix HydrolasesPantothenate Kinase-Associated NeurodegenerationPyrophosphatasesCoenzyme ANudix HydrolasesPyrophosphatases

Identifiers

PMID26052948
PMCPMC4460045
OpenAlexW582705125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.